Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualized monitoring
ABSTRACT
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis
ABSTRACT
RATIONALE: Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resistance. Evidence is needed to inform optimal treatment for these patients.
OBJECTIVES: We compared the effectiveness of longer individualized regimens comprised of bedaquiline for 5 to 8 months, linezolid, and clofazimine to those reinforced with at least 1 third-tier drug and/or longer duration of bedaquiline.
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
ABSTRACT
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
ABSTRACT
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
ABSTRACT
RATIONALE: Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform the optimal duration of bedaquiline.
OBJECTIVES: We emulated a target trial to estimate the effect of three bedaquiline duration treatment strategies (6 months, 7-11 months, ≥ 12 months) on the probability of successful treatment among patients receiving a longer individualized regimen for multidrug-resistant tuberculosis.
Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
ABSTRACT
Pre-print of the endTB results manuscript : “Nine-month, all-oral regimens for rifampin-resistant tuberculosis.”
Find for download the pre-print of the endTB results manuscript (PDF format).
More information on the endTB clinical trial results page.
PowerPoint slides of the endTB trial results presentations at the Union World Conference
You can download the PowerPoint slides of our endTB trial results presentations at the Union World Conference, 15-18 November 2023.
More details on the endTB clinical trial results at this link: https://endtb.org/endtb-clinical-trial-results
Publication: Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
Background: Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens.
